BIC LEN HIV Treatment: New Single-Tablet Regime...

By João L. Carapinha

February 26, 2026

BIC/LEN HIV Treatment Maintains Suppression in Switch Studies Phase 3 results from Gilead Sciences' ARTISTRY-1 and ARTISTRY-2 trials, presented at the 2026 Conference on R...
Merck Portfolio Optimization: Strategic Reorganization for Enhanced Commercia...
Economic Burden NSCLC: A Systematic Review of Healthcare Costs and Resource U...
NICE Updates Type 2 Diabetes Guidelines: Emphasizing Cardiorenal Protection w...
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
National HealthTech Access: Transforming NHS Adoption and Equity
Launch of TrumpRx Drug Pricing: Savings on Essential Medications
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable He...
Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management
Navigating Economic Resilience Through Life Sciences Investment